Tregs

[Petr75]

2024 May 8
Targeted Therapy of Multiple Sclerosis: A Case for Antigen-Specific Tregs
https://pubmed.ncbi.nlm.nih.gov/38786021/

Abstract

Multiple sclerosis is an autoinflammatory condition that results in damage to myelinated neurons in affected patients. While disease-modifying treatments have been successful in slowing the progression of relapsing-remitting disease, most patients still progress to secondary progressive disease that is largely unresponsive to disease-modifying treatments. Similarly, there is currently no effective treatment for patients with primary progressive MS. Innate and adaptive immune cells in the CNS play a critical role in initiating an autoimmune attack and in maintaining the chronic inflammation that drives disease progression. In this review, we will focus on recent insights into the role of T cells with regulatory function in suppressing the progression of MS, and, more importantly, in promoting the remyelination and repair of MS lesions in the CNS. We will discuss the exciting potential to genetically reprogram regulatory T cells to achieve immune suppression and enhance repair locally at sites of tissue damage, while retaining a fully competent immune system outside the CNS. In the future, reprogramed regulatory T cells with defined specificity and function may provide life medicines that can persist in patients and achieve lasting disease suppression after one cycle of treatment.

[ElliotB]

...secondary progressive disease that is largely unresponsive to disease-modifying treatments.

Actually, Ocrevus is thought to be helpful with secondary progressive forms of MS and is recommended for them.



Ocrevus Still Top Therapy for Progressive MS Forms, Report Finds
https://multiplesclerosisnewstoday.com/ ... ort-finds/